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Low frequency of TERT promoter mutations
in gastrointestinal stromal tumors (GISTs)
Nathália C Campanella1, Ricardo Celestino2,3, Ana Pestana2,4, Cristovam Scapulatempo-Neto1,5,
Antonio Talvane de Oliveira6, Maria José Brito7, António Gouveia8, José Manuel Lopes2,9,10,
Denise Peixoto Guimarães1,11, Paula Soares2,10 and Rui M Reis*,1,12,13
Somatic mutations in the promoter region of telomerase reverse transcriptase (TERT) gene, mainly at positions c.−124 and
c.−146 bp, are frequent in several human cancers; yet its presence in gastrointestinal stromal tumor (GIST) has not been
reported to date. Herein, we searched for the presence and clinicopathological association of TERT promoter mutations in
genomic DNA from 130 bona ﬁde GISTs. We found TERT promoter mutations in 3.8% (5/130) of GISTs. The c.−124C4T
mutation was the most common event, present in 2.3% (3/130), and the c.−146C4T mutation in 1.5% (2/130) of GISTs.
No signiﬁcant association was observed between TERT promoter mutation and patient’s clinicopathological features. The present
study establishes the low frequency (4%) of TERT promoter mutations in GISTs. Further studies are required to conﬁrm our
ﬁndings and to elucidate the hypothetical biological and clinical impact of TERT promoter mutation in GIST pathogenesis.
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INTRODUCTION
The telomerase reverse transcriptase (TERT) gene encodes the catalytic
subunit of telomerase that is crucial to maintenance and regulation of
the telomeres.1,2 In normal somatic adult tissues, telomerase activity is
restricted to stem cells, and telomerase reactivation was proposed to be
one of cancer hallmarks.3 Recently, hotspot somatic mutations in the
promoter region of TERT, located − 124 and − 146 bp upstream from
the ATG start site (c.− 124C4T and c.− 146C4T) were reported in
several human cancers, including bladder (~85% of mutated cases),
gliomas (~50%), thyroid (~15%) and melanoma (22–85%).4–9 It was
proposed that both c.− 124C4T and c.− 146C4T mutations create
new binding motif sites (GGAA) of ETS transcription factors leading
to upregulation of TERT levels and protein activity.4,5
Gastrointestinal stromal tumors (GISTs) are the most common
mesenchymal tumor on the gastrointestinal tract characterized by
hotspot mutations in KIT and PDGFRA genes, which are predictive of
imatinib-based therapy response.10,11 Somatic BRAF mutations12–14
and germinative SDHx mutations were reported in a subset of
KIT/PDGFRA wild-type GIST.15,16 Increased telomerase activity was
reported in GISTs and was associated with poor prognosis.17 Yet,
TERT promoter mutation has not been reported in GIST. Herein, we
searched for the presence and clinicopathological association of the
c.− 124C4T and c.− 146C4T TERT promoter mutations in a series
of 130 bona ﬁde GISTs.12,18–20
MATERIALS AND METHODS
One hundred and thirty cases of GIST were selected from the ﬁles of the
Department of Pathology from Barretos Cancer Hospital, Brazil, Centro
Hospitalar S. João and Garcia de Orta Hospital, Portugal. The cases
were retrospectively re-evaluated and classiﬁed according to the WHO
classiﬁcation,21 and were assessed for the mean age, primary localization,
tumor size, National Comprehensive Cancer Network (NCCN) risk
classiﬁcation,22 metastasis and overall survival. The mean age of the patients
was 59.8 years, 52.3% were male and the tumors were located mainly in the
stomach (50%) and the small intestine (32.7%). Most tumors had tumor size
45 cm, high malignancy risk and metastatic potential (Table 1).
The characterization of the mutational status for KIT and PDGFRA was
performed in all GISTs.12,18–20 In addition, the BRAF mutation status was
evaluated in KIT/PDGFRA wild-type GISTs (n= 9) from Barretos Cancer
Hospital and the SDH genes status was evaluated in KIT/PDGFRA/BRAF wild-
type GISTs (n= 18) from Centro Hospitalar S. João.15,16
Tumor genomic DNA was extracted from formalin-ﬁxed and parafﬁn-
embedded tissues using the QIAamp DNA MicroKit (Qiagen, Hilden,
Germany), following the manufacturer’s instructions.19 A fragment of the
TERT promoter was ampliﬁed with PCR using primers 5′-AGTGGATTCGCG
GGCACAGA-3′ and 5′-CAGCGCTGCCTGAAACTC-3′, resulting in a PCR
product of 235 bp, which contained the chr5.hg19:g.1295228C4T and Chr5.
hg19:g.1295250C4T sites of mutations. Alternatively, gene mutations can
be designated based on their upstream location to the ATG initiation codon
of TERT, as c.− 124C4T, and c.− 146C4T, as previously described.7 PCR
was performed with an initial denaturation at 95 °C for 15 min, followed by
40 cycles of 95 °C denaturation for 30 s, 64 °C annealing for 90 s and 72 °C
elongation for 30 s and 72 °C ﬁnal elongation for 7 min. Quality of PCR
products was conﬁrmed with gel electrophoresis. DNA sequencing of the
PCR product was performed using the BigDye Terminator version 3.1 cycle
sequencing kit (Applied Biosystems, Foster City, CA, USA) and an ABI
PRISM 3500 xL Genetic Analyzer (Applied Biosystems). The chromato-
grams were compared with the reference sequence (GeneBank, TERT:
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ENST00000310581). The SPSS 19.0 software (IBM Corp, Armonk, NY,
USA) was used for all statistical analysis. To assess the relationship between
variables, we used the Fisher’s exact test. The P-value established for the
statistics signiﬁcance was o0.05.
RESULTS
We found TERT promoter mutations in 3.8% (5/130) of the GISTs
(Table 2 and Figure 1). The identiﬁed mutations are described in the
LOVD database (https://research.cchmc.org/LOVD2/home.php;
patient IDs 819–823). The c.− 124C4T mutation was the most
common event, present in 2.3% (3/130), and the c.− 146C4T
mutation in 1.5% (2/130) of GISTs. The two mutations occur in a
mutually exclusive manner. No statistical correlation was found
between TERT mutation and GIST clinical or molecular features
(Table 1). Yet, TERT mutations appeared in tumors of slightly older
patients, and no TERT-mutated cases were detected in benign/very-
low malignancy risk GISTs (Table 1).
DISCUSSION
This study describes for the ﬁrst time the occurrence of TERT
promoter mutations (c.− 124C4T and c.− 146C4T) in GISTs, being
present in ~ 4% of the cases. As paired blood or constitutive DNA of
the tumors analyzed in the present study was not available, we cannot
conﬁrm the somatic nature of the c.− 124 or c.− 146 mutations
identiﬁed. However, germline mutations at these hotspots were not
reported in the various TERT studies that performed such paired
(tumor versus normal) analysis.4–7,23–25 In addition, in the COSMIC
database,26 these mutations are described as somatic, and they are not
present in the 1000 Genomes database.27 Therefore, we can almost
certainty assume that the mutations observed in GISTs were somati-
cally acquired.
Previously, we analyzed a series of 36 GISTs and did not identify
any TERT promoter mutation.7 Likewise, Killela et al6 also analyzed
nine GISTs and did not found any TERT promoter mutation. As
identical methodologies were used in all studies, one plausible reason
for this discrepancy is the small number of cases analyzed in the
previous studies.6,7
TERT promoter mutations seem to be widespread in cancer,
although showing tissue speciﬁcity. Killela et al6 suggested that cancers
developing in tissues that are regularly self-renewing, such as in the
gastrointestinal tract, skin and bone marrow, are not likely to harbor
telomere-maintaining mutations, as telomerase is already epigeneti-
cally activated in their precursor cells. In contrast, cancers arising from
cells that are not regularly self-renewing might harbor such
mutations. GISTs ﬁt to the second setting, as they are assumed to
originate from the low-renewal Cajal cells or their precursors.28 GISTs
are prone to exhibit a high risk of disease relapse and metastasis
spreading to distant organs such as the liver, peritoneal surface and
lung.10 Previous reports associate telomerase activity in GIST with
higher tumor malignancy risk, metastasis and worse prognosis.29–31
We found a low frequency of TERT mutations in GIST, but any
Table 1 Association of TERT promoter mutation status and
clinicopathological and molecular features of GISTs
Variable TERT wild type TERT mutated P-value
Mean Age 59.6 65.9 0.351
Primary localization
Esophagus 1 (0.9) 0 0.132
Stomach 62 (53) 3 (60)
Small intestine 37 (31.6) 0
Large intestine 2 (1.7) 1 (20)
Rectum 4 (3.4) 1 (20)
Mesentery 2 (1.7) 0
Retroperitoneum 6 (5.1) 0
Esophagus/stomach 1(0.9) 0
Other 2 (1.7) 0
Tumor size
≤5 cm 41 (36.3) 1 (20) 0.654
45 cm 72 (63.7) 4 (80)
NCCN risk classiﬁcationa
Benign 2 (2.2) 0 0.646
Very low 19 (21.3) 0
Low 18 (20.2) 2 (40)
Intermediate 10 (11.2) 0
High 40 (44.9) 3 (60)
Metastasis
Absent 78 (70.9) 4 (80) 1
Present 32 (29.1) 1 (20)
Overall survival
Dead 23 (27.4) 1 (20) 0.398
Alive 61 (72.6) 4 (80)
KIT/PDGFRA/BRAF status
KIT mutated 83 (66.4) 2 (40) 0.186
PDGFRA mutated 16 (12.8) 0
Wild type 26 (20.8) 3 (60)
Abbreviations: NCCN, National Comprehensive Cancer Network.
aMiettinen and Lasota.22
Table 2 Clinicopathological and molecular data of the GISTs with TERT promoter mutation (clinicopathological and molecular features of
TERT promoter-mutated GISTs)
ID Hospital
Age
(years) Gender
Primary
localization
Tumor
size (cm)
NCCN risk
classiﬁcationa Metastasis
Status at last
follow-up
Follow-up
time (years)
KIT/
PDGFRA/
BRAF muta-
tion status
TERT promo-
ter mutation
Case 44 Barretos 77 Female Stomach 7 Intermediate Absent Alive without cancer 10.71 KIT c.−146C4T
Case 75 Barretos 47 Male Rectum 4 Intermediate Present Alive with cancer 11.71 KIT c.−124C4T
Case 159 S. João 49 Male Stomach 6.5 High Absent Alive without cancer 22 .63 Wild type c.−124C4T
Case 215 S. João 76 Male Stomach 6 Intermediate Absent Alive without cancer 8.78 Wild type c.−124C4T
Case 216 S. João 81 Male Large intestine 12.5 High Absent Death due to cancer 0.02 Wild type c.−146C4T
Abbreviation: NCCN, National Comprehensive Cancer Network.
aMiettinen and Lasota.22
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statistical association was found with tumor aggressiveness; however,
most TERT-mutated GISTs displayed high recurrence risk features.
Although our series is undersized to allow deﬁnitive conclusions, it
would be of interest to further evaluate whether TERT promoter
mutations associate with a higher expression of telomerase in GISTs,
and to assess whether TERT promoter mutations associate with poor
prognosis as reported in other cancers such as cancers of the thyroid,32
melanoma9 and brain.6
On the whole, our study establishes the presence of TERT promoter
mutations in a subset of GISTs (4%). Future studies are required to
validate our ﬁndings and to elucidate the potential biological and
clinical impact of TERT promoter mutation in GIST pathogenesis.
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Figure 1 Electropherogram of TERT promoter mutations. (a) Heterozigotic
c.−124C4T mutation (arrow); (b) Heterozigotic c.−146C4T mutation
(arrow).
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